Issues: Vax Specific

Anthrax

Hepatitis B

Hib

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

 

Components of
Varicella and Zoster Vaccines

Excipients Table
Allergens Table
Components Table

 

Indication

Active immunity against varicella-zoster virus

Prevention of shingles in individuals 60 years and older

Proprietary Name

Varivax

Zostavax

Manufacturer

Merck

Merck

Viability

Live, attenuated

Live, attenuated

Approved Ages

12 months and older

50 years and older

Microorganism

Double-stranded DNA varicella zoster virus, human herpes virus 3, genus Varicella virus

Oka/Merck strain

Dosage, Route

0.5 mL

0.65 mL

Route

Subcutaneous

Subcutaneous

Dose form

Lyophilized powder for suspension

Lyophilized preparation

Appearance

White powder yielding a clear, colorless to pale yellow liquid

Semi-hazy to translucent, off-white to pale yellow liquid

Concentration (per 0.5 mL)

Oka/Merck varicella virus 1350 PFU

Oka/Merck varicella virus 19,400 PFU

Preservatives

None

None

Adjuvant

None

None

Excipients

Sucrose, 25 mg
Hydrolyzed gelatin, 12. 5 mg
Sodium chloride, 3.2 m
Monosodium L-glutamate, 0.5 mg
Sodium phosphate dibasic, 0.45 mg
Potassium phosphate monobasic, 0.08 mg
Potassium chloride, 0.08 mg

Residual components of:

MRC-5 cells including DNA and proteins

 

Trace quantities of:

Sodium phosphate monobasic
Ethylenediaminetetraacetic acid (EDTA)
Neomycin
Fetal bovine serum

Sucrose, 31.16 mg
Hydrolyzed gelatin (porcine), 15.58 mg
Sodium chloride, 3.99 mg
Monosodium L-glutamate, 0.62 mg
Sodium phosphate dibasic, 0.57 mg
Potassium phosphate monobasic, 0.10 mg
Potassium chloride, 0.10 mg

Residual components of:

MRC-5 cells including DNA and proteins

 

Trace quantities of:

Neomycin
Fetal bovine serum

Allergens

Hydrolyzed gelatin, 12.5 mg

Neomycin, trace amounts

Hydrolyzed gelatin, 15.58 mg

Neomycin, trace amounts

Media

MRC-5 human diploid-cell culture

MRC-5 human diploid-cell culture

Packaging

Vial, Single-dose +10 vials of diluent; 10 single-dose vials + 10 vials diluent

Vial, Single-dose +10 vials of diluent; 10 single-dose vials + 10 vials diluent

Routine Storage

-15 C or colder until up to 72 hours before reconstitution, then stored at 2 to 8 C (35-46 F) for up to 72 hours

-15 C or colder until reconstituted for injection

Package Insert Date

10/2013

4/2013

updated 10/22/13

This page was last updated on October 22, 2013

2014 Institute for Vaccine Safety